News | April 03, 2022
JBCPL buys Azmarda trademark for India at Rs 246 crore
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The plant is scheduled to come on stream in September 2024
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
Subscribe To Our Newsletter & Stay Updated
